| Name: | Apremilast EP Impurity F |
| Catalogue No. | VL6770006 |
| CAS No. | N/A |
| Molecular Formula | C20H24N2O7S |
| Molecular Weight | 436.48 g/mol |
| Status | In-Stock |
| IUPAC Name | 2-amino-6-((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)carbamoyl)benzoic acid |
| Synonyms | rac-N-Deacetyl-2-carboxy-(seco-phthalimido) Apremilast |
| Description | Apremilast EP Impurity F (CAS NO.-NA) IUPAC Name-2-amino-6-((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)carbamoyl)benzoic acid. Apremilast is an oral phosphodiesterase 4 inhibitor that have an impact on a wide range of inflammatory mediators involved in psoriasis and psoriatic arthritis, this is a novel treatment that focuses on maintaining a balance between pro-inflammatory and anti-inflammatory signals. |
| References | Schafer, Peter. “Apremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis.” Biochemical Pharmacology, vol. 83, no. 12, June 2012, pp. 1583–90, https://doi.org/10.1016/j.bcp.2012.01.001. |
